Skip to main content
SciBX
Feature Story

Corneal perspectives

By Benjamin Boettner, Associate Editor

Corneal perspectives

Two independent findings could increase the availability of tissue for corneal transplants. A University of California, San Diego-led team has created a new source of limbal stem cells-which are needed for clear vision-by expressing PAX6 in skin epithelial cells, while a Harvard Medical School-led group showed that the ATP-binding cassette transporter ABCB5 is a marker for selection of limbal stem cells with enhanced regenerative potential.1,2

Full Article

Today's Biotech & Pharma News

Taxing Innovation

  • COVER STORY

    Fat chance for cancer cachexia

    With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies may consider targeting the cause of the wasting disease rather than its symptoms. Two independent academic teams have now found evidence that browning of white fat is responsible for cachexia in patients with cancer and propose different strategies to block the process.

  • TRANSLATIONAL NOTES

    AstraZeneca taps the Cambridge wellspring

    AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground in scientific leadership. The company hopes to tap into world-class research through partnerships with nearby institutes.

  • TARGETS & MECHANISMS

    Corneal perspectives

    Two independent findings could increase the availability of tissue for corneal transplants. A UCSD team has identified key factors needed to culture the limbal stem cells necessary for clear vision. A Harvard team has found a marker for enhanced regenerative potential of limbal stem cells and licensed the antibody to stem cell companies Rheacell and Ticeba.

  • TOOLS

    Circling back to basics

    Creating potent and orally bioavailable macrocycles is more challenging than developing small molecules, but a trio of studies could close the gap by proposing new design guidelines, identifying protein-protein interfaces to target and providing a new method to synthesize cyclic peptides.

  • THERAPEUTICS

    This Week in Therapeutics

    Preventing tumor regrowth with FASN inhibitors; promoting wound healing with OR2AT4 activators; treating glaucoma with CASP8 inhibitors; and more...

  • TECHNIQUES

    This Week in Techniques

    A gold plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes; a Camta1-deficient mouse model of ataxia and neurodegenerative disease; a gastric tumor classification system; and more...

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.